ArticleJournal of hematology2023

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone.

Omar Alkharabsheh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.